Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7

P. James B. Dyck, A. González-Duarte, L. Obici, M. Polydefkis, J. F. Wiesman, I. Antonino, W. J. Litchy, Peter J. Dyck

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a rare, life-threatening disease, caused by point mutations in the transthyretin gene. It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy (including sensory, motor, and autonomic impairments) and cardiac dysfunction. Measures used to assess polyneuropathy in other diseases have been tested as endpoints in hATTR amyloidosis clinical trials (i.e. Neuropathy Impairment Score [NIS], NIS-lower limb, and NIS + 7), yet the unique nature of the polyneuropathy in this disease has necessitated modifications to these scales. In particular, the heterogeneous impairment and the aggressive disease course have been key drivers in developing scales that better capture the disease burden and progression of polyneuropathy in hATTR amyloidosis. The modified NIS + 7 (mNIS + 7) scale was specifically designed to assess polyneuropathy impairment in patients with hATTR amyloidosis, and has been the primary endpoint in two recent, phase III studies in this disease. The mNIS + 7 uses highly standardized, quantitative, and referenced assessments to quantify decreased muscle weakness, muscle stretch reflexes, sensory loss, and autonomic impairment. Physicians using this scale in clinical trials should be specifically trained and monitored to minimize variability. This article discusses the different scales that have been/are being used to assess polyneuropathy in patients with hATTR amyloidosis, their correlation with other disease assessments, and reflects on how and why scales have evolved to the latest iteration of mNIS + 7.

Original languageEnglish (US)
Article number116424
JournalJournal of the neurological sciences
StatePublished - Oct 15 2019


  • Hereditary transthyretin-mediated amyloidosis
  • Modified neuropathy impairment score+7
  • Neuropathy impairment score
  • Polyneuropathy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7'. Together they form a unique fingerprint.

Cite this